|
1
|
Bray F, Laversanne M, Weiderpass E and
Soerjomataram I: The ever-increasing importance of cancer as a
leading cause of premature death worldwide. Cancer. 127:3029–3030.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality Worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garon EB, Hellmann MD, Rizvi NA, Carcereny
E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L,
et al: Five-Year overall survival for patients with advanced
non-small-cell lung cancer treated with pembrolizumab: Results from
the phase I KEYNOTE-001 Study. J Clin Oncol. 37:2518–2527. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar
|
|
5
|
Cortes J, Cescon DW, Rugo HS, Nowecki Z,
Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et
al: Pembrolizumab plus chemotherapy versus placebo plus
chemotherapy for previously untreated locally recurrent inoperable
or metastatic triple-negative breast cancer (KEYNOTE-355): A
randomised, placebo-controlled, double-blind, phase 3 clinical
trial. Lancet. 396:1817–1828. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Licitra L and Vermorken JB: Is there still
a role for neoadjuvant chemotherapy in head and neck cancer? Ann
Oncol. 15:7–11. 2004. View Article : Google Scholar
|
|
7
|
Wang H and Mao X: Evaluation of the
efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des
Devel Ther. 14:2423–2433. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Salvà F and Felip E: Neoadjuvant
chemotherapy in early-stage non-small cell lung cancer. Transl Lung
Cancer Res. 2:398–402. 2013.PubMed/NCBI
|
|
9
|
Peyton CC, Tang D, Reich RR, Azizi M,
Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ,
et al: Downstaging and survival outcomes associated with
neoadjuvant chemotherapy regimens among patients treated with
cystectomy for muscle-invasive bladder cancer. JAMA Oncol.
4:1535–1542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Poggio F, Bruzzone M, Ceppi M, Pondé NF,
La Valle G, Del Mastro L, de Azambuja E and Lambertini M:
Platinum-based neoadjuvant chemotherapy in triple-negative breast
cancer: A systematic review and meta-analysis. Ann Oncol.
29:1497–1508. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zinner R, Johnson JM, Tuluc M, Curry JM,
Luginbuhl A, Fundakowski CC, Yampolsky A, Goldman RR, Solomides CC,
Mardekian S, et al: Neoadjuvant nivolumab (N) plus weekly
carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable
locally advanced head and neck cancer. Ann Oncol. 31(Suppl 4):
S6822020. View Article : Google Scholar
|
|
12
|
Loibl S, Untch M, Burchardi N, Huober J,
Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C,
et al: A randomised phase II study investigating durvalumab in
addition to an anthracycline taxane-based neoadjuvant therapy in
early triple-negative breast cancer: Clinical results and biomarker
analysis of GeparNuevo study. Ann Oncol. 30:1279–1288. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rothschild SI, Zippelius A, Eboulet EI,
Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M,
Lardinois D, Gelpke H, et al: SAKK 16/14: Durvalumab in addition to
neoadjuvant chemotherapy in patients with Stage IIIA(N2)
Non-small-cell lung cancer-a multicenter single-arm phase II trial.
J Clin Oncol. 39:2872–2880. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pauken KE, Sammons MA, Odorizzi PM, Manne
S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, et al:
Epigenetic stability of exhausted T cells limits durability of
reinvigoration by PD-1 blockade. Science. 354:1160–1165. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Blake SJ, Yong MC, Harjunpää H,
Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ and
Teng MW: Improved efficacy of neoadjuvant compared to adjuvant
immunotherapy to eradicate metastatic disease. Cancer Discov.
6:1382–1399. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
|
17
|
Hellmann MD, Chaft JE, William WN Jr,
Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG and
Kris MG: Pathological response after neoadjuvant chemotherapy in
resectable non-small-cell lung cancers: Proposal for the use of
major pathological response as a surrogate endpoint. Lancet Oncol.
15:e42–e50. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Travis WD, Dacic S, Wistuba I, Sholl L,
Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, et
al: IASLC Multidisciplinary recommendations for pathologic
assessment of lung cancer resection specimens after neoadjuvant
therapy. J Thorac Oncol. 15:709–740. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pataer A, Kalhor N, Correa AM, Raso MG,
Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, et al:
Histopathologic response criteria predict survival of patients with
resected lung cancer after neoadjuvant chemotherapy. J Thorac
Oncol. 7:825–832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B,
Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello
S, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab in
untreated oral cavity squamous cell carcinoma: A phase 2 open-label
randomized clinical trial. JAMA Oncol. 6:1563–1570. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferrarotto R, Bell D, Rubin ML, Hutcheson
KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman DK, Warneke
CL, et al: Impact of Neoadjuvant durvalumab with or without
tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy
in patients with oropharynx cancer: CIAO trial results. Clin Cancer
Res. 26:3211–3219. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Uppaluri R, Campbell KM, Egloff AM,
Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson
R, Pipkorn P, et al: Neoadjuvant and adjuvant pembrolizumab in
resectable locally advanced, human papillomavirus-unrelated head
and neck cancer: A multicenter, Phase II trial. Clin Cancer Res.
26:5140–5152. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uppaluri R, Chernock R, Mansour M, Jackson
R, Rich J, Pipkorn P, Paniello RC, Puram S, Zevallos JP, Annino DJ,
et al: Enhanced pathologic tumor response with two cycles of
neoadjuvant pembrolizumab in surgically resectable, locally
advanced HPV-negative head and neck squamous cell carcinoma
(HNSCC). J Clinical Oncol. 39:60082021. View Article : Google Scholar
|
|
24
|
Leidner R, Crittenden M, Young K, Xiao H,
Wu Y, Couey MA, Patel AA, Cheng AC, Watters AL, Bifulco C, et al:
Neoadjuvant immunoradiotherapy results in high rate of complete
pathological response and clinical to pathological downstaging in
locally advanced head and neck squamous cell carcinoma. J
Immunother Cancer. 9:e0024852021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vos JL, Elbers JBW, Krijgsman O, Traets
JH, Qiao X, Leun AMV, Lubeck Y, Seignette IM, Smit LA, Willems SM,
et al: Neoadjuvant immunotherapy with nivolumab and ipilimumab
induces major pathological responses in patients with head and neck
squamous cell carcinoma. Nature Commun. 12:73482021. View Article : Google Scholar
|
|
26
|
Knochelmann HM, Horton JD, Liu S, Armeson
K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y,
Graboyes EM, et al: Neoadjuvant presurgical PD-1 inhibition in oral
cavity squamous cell carcinoma. Cell Rep Medicine. 2:1004262021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wise-Draper TM, Takiar V, Mierzwa ML,
Casper K, Palackdharry S, Worden FP, Old MO, Dunlap NE, Kaczmar JM,
Patil Y, et al: Association of pathological response to neoadjuvant
pembrolizumab with tumor PD-L1 expression and high disease-free
survival (DFS) in patients with resectable, local-regionally
advanced, head and neck squamous cell carcinoma (HNSCC). J Clinical
Oncol. 39:60062021. View Article : Google Scholar
|
|
28
|
Ferris RL, Spanos WC, Leidner R, Gonçalves
A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier
H, et al: Neoadjuvant nivolumab for patients with resectable
HPV-positive and HPV-negative squamous cell carcinomas of the head
and neck in the CheckMate 358 trial. J Immunother Cancer.
9:e0025682021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmid P, Salgado R, Park YH,
Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent
R, et al: Pembrolizumab plus chemotherapy as neoadjuvant treatment
of high-risk, early-stage triple-negative breast cancer: Results
from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann
Oncol. 31:569–581. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Foldi J, Silber A, Reisenbichler E, Singh
K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin
D, et al: Neoadjuvant durvalumab plus weekly nab-paclitaxel and
dose-dense doxorubicin/cyclophosphamide in triple-negative breast
cancer. NPJ Breast Cancer. 7:92021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mittendorf EA, Zhang H, Barrios CH, Saji
S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al:
Neoadjuvant atezolizumab in combination with sequential
nab-paclitaxel and anthracycline-based chemotherapy versus placebo
and chemotherapy in patients with early-stage triple-negative
breast cancer (IMpassion031): A randomised, double-blind, phase 3
trial. Lancet. 396:1090–1100. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schmid P, Cortes J, Pusztai L, McArthur H,
Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al:
Pembrolizumab for early triple-negative breast cancer. N Engl J
Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai
L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, et al:
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic
complete response in women with early-stage breast cancer: An
analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.
JAMA Oncol. 6:676–684. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pusztai L, Yau C, Wolf DM, Han HS, Du L,
Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, et al:
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative
stage II/III breast cancer: Results from the adaptively randomized
I-SPY2 trial. Cancer cell. 39:989–998.e5. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yam C, Mittendorf EA, Sun R, Huo L,
Damodaran S, Rauch GM, Candelaria RP, Adrada BE, Seth S, Symmans
WF, et al: Neoadjuvant atezolizumab (atezo) and nab-paclitaxel
(nab-p) in patients (pts) with triple-negative breast cancer (TNBC)
with suboptimal clinical response to doxorubicin and
cyclophosphamide (AC). J Clin Oncol. 39:5922021. View Article : Google Scholar
|
|
36
|
McArthur H, Shiao S, Karlan S, Amersi F,
Arnold B, Basho R, Burnison M, Chung A, Chung C, Dang C, et al:
Abstract P3-09-09: Pre-operative pembrolizumab (Pembro) with
radiation therapy (RT) in patients with operable triple-negative
breast cancer (TNBC). Cancer Res. 81:P3-09-092021. View Article : Google Scholar
|
|
37
|
Gianni L, Huang CS, Egle D, Bermejo B,
Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, et
al: Pathologic complete response (pCR) to neoadjuvant treatment
with or without atezolizumab in triple-negative, early high-risk
and locally advanced breast cancer: NeoTRIP Michelangelo randomized
study. Ann Oncol. 33:534–543. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dieci MV, Guarneri V, Tosi A, Bisagni G,
Musolino A, Spazzapan S, Moretti G, Vernaci GM, Griguolo G,
Giarratano T, et al: Neoadjuvant chemotherapy and immunotherapy in
luminal b-like breast cancer: Results of the phase II GIADA trial.
Clin Cancer Res. 28:308–317. 2022. View Article : Google Scholar
|
|
39
|
Forde PM, Chaft JE, Smith KN, Anagnostou
V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR,
Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung
cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bott MJ, Yang SC, Park BJ, Adusumilli PS,
Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E,
et al: Initial results of pulmonary resection after neoadjuvant
nivolumab in patients with resectable non-small cell lung cancer. J
Thorac Cardiovasc Surg. 158:269–276. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Reuss JE, Anagnostou V, Cottrell TR, Smith
KN, Verde F, Zahurak M, Lanis M, Murray JC, Chan HY, McCarthy C, et
al: Neoadjuvant nivolumab plus ipilimumab in resectable non-small
cell lung cancer. J Immunother Cancer. 8:e0012822020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bar J, Urban D, Ofek E, Ackerstein A,
Redinsky I, Golan N, Kamer I, Simansky D, Onn A, Raskin S, et al:
Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell
lung cancer (NSCLC): Updated report of a phase i study, MK3475-223.
J Clin Oncol. 37:8534. 2019. View Article : Google Scholar
|
|
43
|
Shu CA, Gainor JF, Awad MM, Chiuzan C,
Grigg CM, Pabani A, Garofano RF, Stoopler MB, Cheng SK, White A, et
al: Neoadjuvant atezolizumab and chemotherapy in patients with
resectable non-small-cell lung cancer: An open-label, multicentre,
single-arm, phase 2 trial. Lancet Oncol. 21:786–795. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Provencio M, Nadal E, Insa A,
García-Campelo MR, Casal-Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, De Castro, Carpeño J, et al:
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell
lung cancer (NADIM): An open-label, multicentre, single-arm, phase
2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao S, Li N, Gao S, Xue Q, Ying J, Wang S,
Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor
(Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Besse B, Adam J, Cozic N, Chaput N,
Planchard D, Mezquita L, Mezquita JR, Mezquita P, Mezquita C,
Mezquita A, et al: 1215O-SC Neoadjuvant atezolizumab (A) for
resectable non-small cell lung cancer (NSCLC): Results from the
phase II PRINCEPS trial. Ann Oncol. 31(Suppl): S794–S795. 2020.
View Article : Google Scholar
|
|
47
|
Lee J, Chaft J, Nicholas A, Patterson A,
Waqar S, Toloza E, Haura E, Raz D, Reckamp K, Merritt R, et al:
PS01.05 Surgical and clinical outcomes with neoadjuvant
Atezolizumab in resectable stage IB-IIIB NSCLC: LCMC3 trial primary
analysis. J Thorac Oncol. 16(Suppl): S59–S61. 2021. View Article : Google Scholar
|
|
48
|
Zhao ZR, Yang CP, Chen S, Yu H, Lin YB,
Lin YB, Qi H, Jin JT, Lian SS, Wang YZ, et al: Phase 2 trial of
neoadjuvant toripalimab with chemotherapy for resectable stage III
non-small-cell lung cancer. Oncoimmunology. 10:19960002021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Eichhorn F, Klotz LV, Kriegsmann M,
Bischoff H, Schneider MA, Muley T, Kriegsmann K, Haberkorn U,
Heussel CP, Savai R, et al: Neoadjuvant anti-programmed death-1
immunotherapy by pembrolizumab in resectable non-small cell lung
cancer: First clinical experience. Lung Cancer. 153:150–157. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cascone T, William WN Jr, Weissferdt A,
Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L,
Reuben A, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab
in operable non-small cell lung cancer: The phase 2 randomized
NEOSTAR trial. Nat Med. 27:504–514. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Altorki NK, McGraw TE, Borczuk AC, Saxena
A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, et
al: Neoadjuvant durvalumab with or without stereotactic body
radiotherapy in patients with early-stage non-small-cell lung
cancer: A single-centre, randomised phase 2 trial. Lancet Oncol.
22:824–835. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tong BC, Gu L, Wang X, Wigle DA, Phillips
JD, Harpole DH Jr, Klapper JA, Sporn T, Ready NE, D'Amico TA, et
al: Perioperative outcomes of pulmonary resection after neoadjuvant
pembrolizumab in patients with non-small cell lung cancer. J Thorac
Cardiovasc Surg. 163:427–436. 2022. View Article : Google Scholar
|
|
53
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gu Y, Chen X, Wang D, Ding M, Xue L, Zhen
F, Xu J, Wang M, Li Y, Sun N, et al: 175P A study of neoadjuvant
sintilimab combined with triplet chemotherapy of lipo-paclitaxel,
cisplatin, and S-1 for resectable esophageal squamous cell
carcinoma (ESCC). Ann Oncol. 31(Suppl 6): S1307–S1308. 2020.
View Article : Google Scholar
|
|
55
|
Li H, Li C, Zheng Y, Zhao S, Chen X, Han
Y, Xiang J and Wu Y: Preoperative combination of pembrolizumab with
chemoradiation for patients with locally advanced esophageal
squamous cell carcinoma: Mid-term results of NCT03604991. Dis
Esophagus. 33:2020 View Article : Google Scholar
|
|
56
|
Li C, Zhao S, Zheng Y, Han Y, Chen X,
Cheng Z, Wu Y, Feng X, Qi W, Chen K, et al: Preoperative
pembrolizumab combined with chemoradiotherapy for oesophageal
squamous cell carcinoma (PALACE-1). Eur J Cancer. 144:232–241.
2021. View Article : Google Scholar
|
|
57
|
van den Ende T, de Clercq NC, van Berge
Henegouwen MI, Gisbertz SS, Geijsen ED, Verhoeven RHA, Meijer SL,
Schokker S, Dings MPG, Bergman JJGHM, et al: Neoadjuvant
chemoradiotherapy combined with atezolizumab for resectable
esophageal adenocarcinoma: A single-arm phase ii feasibility trial
(PERFECT). Clin Cancer Res. 27:3351–3359. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang Z, Hong ZN, Xie S, Lin W, Lin Y, Zhu
J, Yang X, Lin Z, Lin J and Kang M: Neoadjuvant sintilimab plus
chemotherapy for locally advanced esophageal squamous cell
carcinoma: A single-arm, single-center, phase 2 trial (ESONICT-1).
Ann Transl Med. 9:16232021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xing W, Zhao L, Zheng Y, Liu B, Liu X, Li
T, Zhang Y, Ma B, Yang Y, Shang Y, et al: The Sequence of
chemotherapy and toripalimab might influence the efficacy of
neoadjuvant chemoimmunotherapy in locally advanced esophageal
squamous cell Cancer-A phase ii study. Front Immunol.
12:7724502021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang Z: Neoadjuvant camrelizumab combined
with chemotherapy and apatinib for locally advanced thoracic
esophageal squamous cell carcinoma (ESCC): A single-arm,
open-label, phase Ib study. J Clin Oncol. 39:4047. 2021. View Article : Google Scholar
|
|
61
|
Xu W, Jiang Y, Wang C, Wu J, Li J, Hu Y,
Lu W, Shen D, Wang Y and Chen Q: The efficacy and safety of
neoadjuvant camrelizumab and chemotherapy for locally advanced
thoracic esophageal squamous cell carcinoma. J Clin Oncol. 40(Suppl
4): S2782022. View Article : Google Scholar
|
|
62
|
Liu J, Li J, Lin W, Shao D, Depypere L,
Zhang Z, Li Z, Cui F, Du Z, Zeng Y, et al: Neoadjuvant camrelizumab
plus chemotherapy for resectable, locally advanced esophageal
squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2
study. Int J Cancer. 151:128–137. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
He W, Leng X, Mao T, Luo X, Zhou L, Yan J,
Peng L, Fang Q, Liu G, Wei X, et al: Toripalimab plus paclitaxel
and carboplatin as neoadjuvant therapy in locally advanced
resectable esophageal squamous cell carcinoma. Oncologist.
27:e18–e28. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H,
Zhu L, Shen Y, Zhang H, Sun Y, et al: Multicenter, single-arm,
phase II trial of camrelizumab and chemotherapy as neoadjuvant
treatment for locally advanced esophageal squamous cell carcinoma.
J Immunother Cancer. 10:e0042912022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kelly RJ, Smith KN, Anagnostou V, Thompson
E, Hales RK, James Battafarano RJ, Voong KR, Yang SC, Feliciano JL,
Shin EJ, et al: Neoadjuvant nivolumab plus concurrent
chemoradiation in stage II/III esophageal/gastroesophageal junction
cancer. J Clin Oncol. 37:1422019. View Article : Google Scholar
|
|
66
|
Liu Y, Han G, Li H, Zhao Y, Zhuang J, Wang
G, Li B, Wang J, Li Z, Xia Q, et al: Camrelizumab combined with
FOLFOX as neoadjuvant therapy for resectable locally advanced
gastric and gastroesophageal junction adenocarcinoma. J Clin Oncol.
38:45362020. View Article : Google Scholar
|
|
67
|
Shah MA, Almhanna K, Iqbal S, Thakkar P,
Schneider BJ, Yantiss R, Wu Y, Futamura E, Port JL, Spinelli C, et
al: Multicenter, randomized phase II study of neoadjuvant
pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal
adenocarcinoma (EAC). J Clin Oncol. 39:40052021. View Article : Google Scholar
|
|
68
|
Sun W, Saeed A, Al-Rajabi RMT, Kasi A,
Veeramachaneni NK, Al-Kasspooles MM, Baranda JC, Phadnis M, Godwin
AK, Olyaee M, et al: A phase II study of perioperative mFOLFOX
chemotherapy plus pembrolizumab combination in patients with
potentially resectable adenocarcinoma of the esophageal,
gastroesophageal junction (GEJ), and stomach. J Clin Oncol.
40:3292022. View Article : Google Scholar
|
|
69
|
Tao K, Yin Y, Lin Y, Li W, Li R, Liu W,
Xiong Z, Zeng X, Cai M, Wu C and Zhang P: Neoadjuvant PD-1
inhibitor tislelizumab combined with s-1 plus oxaliplatin in
patients with local advanced gastric cancer or gastroesophageal
junction adenocarcinoma: Interim results of a single-arm, phase II
trial. J Clin Oncol. 40:3002022. View Article : Google Scholar
|
|
70
|
Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D,
Wang W, Wang H, Wang H, He K, et al: Efficacy and safety of
neoadjuvant sintilimab, oxaliplatin and capecitabine in patients
with locally advanced, resectable gastric or gastroesophageal
junction adenocarcinoma: Early results of a phase 2 study. J
Immunother Cancer. 10:e0036352022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ho WJ, Zhu Q, Durham J, Popovic A, Xavier
S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, et al:
Neoadjuvant cabozantinib and nivolumab converts locally advanced
HCC into resectable disease with enhanced antitumor immunity. Nat
Cancer. 2:891–903. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Su Y, Lin Y, Hsiao C, Ou D, Chen S, Wu Y,
Lee W, Lin J, Hsu C, Ho M, et al: P-124 Nivolumab plus ipilimumab
as neoadjuvant therapy for potentially resectable hepatocellular
carcinoma. Ann Oncol. 32(Suppl): S1412021. View Article : Google Scholar
|
|
73
|
Kaseb AO, Hasanov E, Cao HST, Xiao L,
Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, et
al: Perioperative nivolumab monotherapy versus nivolumab plus
ipilimumab in resectable hepatocellular carcinoma: A randomised,
open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 7:208–218.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Marron TU, Fiel MI, Hamon P, Fiaschi N,
Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, et al:
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A
single-arm, open-label, phase 2 trial. Lancet Gastroenterol
Hepatol. 7:219–229. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gao J, Karam JA, Tannir NM, Campbell MT,
Tidwell RS, Ahrar K, Rao P, Ng CS, Jonasch E, Matin SF, et al: A
pilot randomized study evaluating nivolumab (nivo) or nivo +
bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with
metastatic renal cell carcinoma (MRCC) eligible for cytoreductive
nephrectomy, metastasectomy or post-treatment biopsy (Bx). J Clin
Oncol. 37:45012019. View Article : Google Scholar
|
|
76
|
Karam JA, Msaouel P, Matin SF, Campbell
MT, Zurita AJ, Shah AY, Wistuba II, Haymaker CL, Marmonti E, Duose
DY, et al: A phase II study of sitravatinib (Sitra) in combination
with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for
locally-advanced clear cell renal cell carcinoma (accRCC). J Clin
Oncol. 39:3122021. View Article : Google Scholar
|
|
77
|
Gorin MA, Patel HD, Rowe SP, Hahn NM,
Hammers HJ, Pons A, Trock BJ, Pierorazio PM, Nirschl TR, Salles DC,
et al: Neoadjuvant nivolumab in patients with high-risk
nonmetastatic renal cell carcinoma. Eur Urol Oncol. 5:113–117.
2022. View Article : Google Scholar :
|
|
78
|
Bex A, Abu-Ghanem Y, Thienen JVV,
Graafland N, Lagerveld B, Zondervan P, Beerlage H, van Moorselaar
J, Kockx M, Van Dam PJ, et al: Efficacy, safety, and biomarker
analysis of neoadjuvant avelumab/axitinib in patients (pts) with
localized renal cell carcinoma (RCC) who are at high risk of
relapse after nephrectomy (NeoAvAx). J Clin Oncol. 40:2892022.
View Article : Google Scholar
|
|
79
|
Carlo MI, Attalla K, Mazaheri Y, Gupta S,
Yildirim O, Murray SJ, Coskey DT, Kotecha R, Lee CH, Feldman DR, et
al: Phase II study of neoadjuvant nivolumab in patients with
locally advanced clear cell renal cell carcinoma undergoing
nephrectomy. Eur Urology. 81:570–573. 2022. View Article : Google Scholar
|
|
80
|
Chalabi M, Fanchi LF, Dijkstra KK, Van den
Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C,
Beets GL, Snaebjornsson P, et al: Neoadjuvant immunotherapy leads
to pathological responses in MMR-proficient and MMR-deficient
early-stage colon cancers. Nat Med. 26:566–576. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yuki S, Bando H, Tsukada Y, Inamori K,
Komatsu Y, Homma S, Uemura M, Kato T, Kotani D, Fukuoka F, et al:
SO-37 Short-term results of VOLTAGE-A: Nivolumab monotherapy and
subsequent radical surgery following preoperative chemoradiotherapy
in patients with microsatellite stability and microsatellite
instability-high, locally advanced rectal cancer (EPOC 1504). Ann
Oncol. 31:S230–S231. 2020. View Article : Google Scholar
|
|
82
|
Avallone A, De Stefano A, Pace U, Catteau
A, Di Gennaro E, Tatangelo F, Boquet I, Cassata A, Costantini S, De
Franciscis S, et al: 491P Neoadjuvant nivolumab in early stage
colorectal cancer. Ann Oncol. 31(Suppl 4): S4492020. View Article : Google Scholar
|
|
83
|
Rahma OE, Yothers G, Hong TS, Russell MM,
You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, et
al: Use of total neoadjuvant therapy for locally advanced rectal
cancer: Initial results from the pembrolizumab arm of a phase 2
randomized clinical trial. JAMA Oncol. 7:1225–1230. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Salvatore L, Bensi M, Corallo S, Bergamo
F, Pellegrini I, Rasola C, Borelli B, Tamburini E, Randon G,
Galuppo S, et al: O-12 Phase II study of preoperative
chemoradiotherapy plus avelumab in patients with locally advanced
rectal cancer: The AVANA study. Ann Oncol. 32(Suppl 3): S2232021.
View Article : Google Scholar
|
|
85
|
Tamberi S, Grassi E, Corbelli J, Papiani
G, Barbera MA, Zingaretti C, Moretti CC, Montroni I, Petracci E,
Caruso D, et al: A phase II study of capecitabine plus concomitant
radiation therapy followed by durvalumab (MEDI4736) as preoperative
treatment in rectal cancer: PANDORA study first-stage
(NCT04083365). Tumori. 107:92–93. 2021.
|
|
86
|
Shamseddine A, Zeidan Y, Bouferraa Y,
Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al
Awabdeh T, et al: Efficacy and safety of neoadjuvant short-course
radiation followed by mFOLFOX-6 plus avelumab for locally-advanced
rectal adenocarcinoma: Averectal study. Ann Oncol. 32(Suppl):
S2152021. View Article : Google Scholar
|
|
87
|
Carrasco J, Schröder D, Sinapi I, De
Cuyper A, Beniuga G, Delmarcelle S, van Laethem JL, Huyghe N, Bar
I, Hendlisz A, et al: 397P R-IMMUNE interim analysis: A phase Ib/II
study to evaluate safety and efficacy of atezolizumab combined with
radio-chemotherapy in a preoperative setting for patients with
localized rectal cancer. Ann Oncol. 32(Suppl 5): S5372021.
View Article : Google Scholar
|
|
88
|
Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang
M, Lan P, Wu X, Wang C, Cao W, et al: Neoadjuvant PD-1 blockade
with toripalimab, with or without celecoxib, in mismatch
repair-deficient or microsatellite instability-high, locally
advanced, colorectal cancer (PICC): A single-centre,
parallel-group, non-comparative, randomised, phase 2 trial. Lancet
Gastroenterol Hepatol. 7:38–48. 2022. View Article : Google Scholar
|
|
89
|
Necchi A, Raggi D, Gallina A, Madison R,
Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E,
Pederzoli F, et al: Updated results of PURE-01 with preliminary
activity of neoadjuvant pembrolizumab in patients with
Muscle-invasive bladder carcinoma with variant histologies. Eur
Urol. 77:439–446. 2020. View Article : Google Scholar
|
|
90
|
Powles T, Kockx M, Rodriguez-Vida A, Duran
I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G,
Herranz UA, et al: Clinical efficacy and biomarker analysis of
neoadjuvant atezolizumab in operable urothelial carcinoma in the
ABACUS trial. Nat Med. 25:1706–1714. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Szabados B, Rodriguez-Vida A, Durá I,
Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA,
Protheroe A, Ravaud A, et al: Toxicity and surgical complication
rates of neoadjuvant atezolizumab in patients with Muscle-invasive
bladder cancer undergoing radical cystectomy: Updated safety
results from the ABACUS trial. Eur Urol Oncol. 4:456–463. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Gao J, Navai N, Alhalabi O, Siefker-Radtke
A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC,
et al: Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with
cisplatin-ineligible operable high-risk urothelial carcinoma. Nat
Med. 26:1845–1851. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wei XX, McGregor BA, Lee RJ, Gao X,
Kilbridge KL, Preston MA, Mossanen M, Ingham MD, Steele GS, Klein
A, et al: Durvalumab as neoadjuvant therapy for muscle-invasive
bladder cancer: Preliminary results from the Bladder Cancer Signal
Seeking Trial (BLASST)-2. J Clin Oncol. 38:507. 2020. View Article : Google Scholar
|
|
94
|
Grande E, Guerrero F, Puente J, Galante I,
Duran I, Dominguez M, Gordoa TA, Burgos J, Font A, Pinto A, et al:
DUTRENEO Trial: A randomized phase II trial of DUrvalumab and
TREmelimumab versus chemotherapy as a NEOadjuvant approach to
muscle-invasive urothelial bladder cancer (MIBC) patients (pts)
prospectively selected by an interferon (INF)-gamma immune
signature. J Clin Oncol. 38:50122020. View Article : Google Scholar
|
|
95
|
Rodriguez-Moreno JF, de Velasco G,
Alvarez-Fernandez C, Collado R, Fernandez-Rodriguez R, Vazquez
Estevez S, Virizuela Echaburu JA, Gajate Borau P, Font A, Lainez N,
et al: 761P Impact of the combination of durvalumab (MEDI4736) plus
olaparib (AZD2281) administered prior to surgery in the molecular
profile of resectable urothelial bladder cancer. NEODURVARIB trial.
Ann Oncol. 31(Suppl 4): S5892020. View Article : Google Scholar
|
|
96
|
Hoimes CJ, Adra N, Fleming MT,
Kaimakliotis HZ, Picus J, Smith ZL, Walling R, Alter RS, Kassar M,
Wang J, et al: Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and
chemotherapy for locally advanced urothelial cancer (laUC): Final
results from the cisplatin (C)-eligible cohort of HCRN GU14-188. J
Clin Oncol. 38:50472020. View Article : Google Scholar
|
|
97
|
Kaimakliotis HZ, Adra N, Kelly WK,
Trabulsi EJ, Lauer RC, Picus J, Smith ZL, Walling R, Masterson TA,
Adra N, et al: Phase II neoadjuvant (N-) gemcitabine (G) and
pembrolizumab (P) for locally advanced urothelial cancer (laUC):
Interim results from the cisplatin (C)-ineligible cohort of.
GU14–188. J Clin Oncol. 38:50192020. View Article : Google Scholar
|
|
98
|
van Dijk N, Gil-Jimenez A, Silina K,
Hendricksen K, Smit LA, de Feijter JM, van Montfoort ML, van
Rooijen C, Peters D, Broeks A, et al: Preoperative ipilimumab plus
nivolumab in locoregionally advanced urothelial cancer: The NABUCCO
trial. Nat Med. 26:1839–1844. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Van Dorp J, Suelmann BBM, Mehra N, Van
Montfoort M, Van Dijk N, Hendricksen K, de Feijter J, Boellaard T,
Daletzakis A, Blank CU, et al: LBA31 High- vs low-dose
pre-operative ipilimumab and nivolumab in locoregionally advanced
urothelial cancer (NABUCCO cohort 2). Ann Oncol. 32(Suppl 5):
S1305–S1306. 2021. View Article : Google Scholar
|
|
100
|
Natesan DV, Zhang L, Oh DY, Porten SP,
Meng M, Pruthi R, Cooperberg MR, Carroll P, Chou J, Borno H, et al:
Updated results of phase II trial using escalating doses of
neoadjuvant atezolizumab for cisplatin-ineligible patients with
nonmetastatic urothelial cancer (NCT02451423). J Clin Oncol.
39:e165102021. View Article : Google Scholar
|
|
101
|
Grivas P, Yin J, Koshkin VS, Cole S, Jain
RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, et al:
PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N)
without or with lirilumab (L) in cisplatin-ineligible patients
(pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol.
39:45182021. View Article : Google Scholar
|
|
102
|
Cathomas R, Rothschild S, Hayoz S, Spahn
M, Schardt J, Seiler R, Erdmann A, Aeppli S, Mach N, Strebel R, et
al: Safety and efficacy of perioperative cisplatin/gemcitabine
(cis/gem) and durvalumab (durva) for operable muscle-invasive
urothelial carcinoma (MIUC): SAKK 06/17. J Clin Oncol. 39:4302021.
View Article : Google Scholar
|
|
103
|
Rose TL, Harrison MR, Deal AM, Ramalingam
S, Whang YE, Brower B, Dunn M, Osterman CK, Heiling HM, Bjurlin MA,
et al: Phase II study of gemcitabine and Split-Dose cisplatin plus
pembrolizumab as neoadjuvant therapy before radical cystectomy in
patients with muscle-invasive bladder cancer. J Clin Oncol.
39:3140–3148. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie
H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, et
al: Neoadjuvant atezolizumab with gemcitabine and cisplatin in
patients with muscle-invasive bladder cancer: A multicenter,
Single-Arm, phase II trial. J Clin Oncol. 40:1312–1322. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Blank CU, Rozeman EA, Fanchi LF, Sikorska
K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M,
Philips D, Broeks A, et al: Neoadjuvant versus adjuvant ipilimumab
plus nivolumab in macroscopic stage III melanoma. Nat Med.
24:1655–1661. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Amaria RN, Reddy SM, Tawbi HA, Davies MA,
Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, et al:
Neoadjuvant immune checkpoint blockade in high-risk resectable
melanoma. Nat Med. 24:1649–1654. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Amaria RN, Postow MA, Tetzlaff MT, Ross
MI, Glitza IC, McQuade JL, Wong MKK, Gershenwald JE, Goepfert R,
Keung EJY, et al: Neoadjuvant and adjuvant nivolumab (nivo) with
anti-LAG3 antibody relatlimab (rela) for patients (pts) with
resectable clinical stage III melanoma. J Clin Oncol. 39:9502.
2021. View Article : Google Scholar
|
|
108
|
Rozeman EA, Menzies AM, van Akkooi ACJ,
Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O,
Sikorska K, Eriksson H, et al: Identification of the optimal
combination dosing schedule of neoadjuvant ipilimumab plus
nivolumab in macroscopic stage III melanoma (OpACIN-neo): A
multicentre, phase 2, randomised, controlled trial. Lancet Oncol.
20:948–960. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Huang AC, Xu X, Orlowski RJ, George SM,
Chilukuri L, Kozlov A, Carberry M, Giles L, McGettigan S, Kreider
K, et al: Abstract CT181: Safety, activity, and biomarkers for
neoadjuvant anti- PD-1 therapy in melanoma. Cancer Res. 78:CT181.
2018. View Article : Google Scholar
|
|
110
|
Huang AC, Orlowski RJ, Xu X, Mick R,
George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, et
al: A single dose of neoadjuvant PD-1 blockade predicts clinical
outcomes in resectable melanoma. Nat Med. 25:454–461. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang X, Cui C, Si L, Li C, Dai J, Mao L,
Bai X, Chi J, Sheng X, Kong Y, et al: A phase Ib clinical trial of
neoadjuvant OrienX010, an oncolytic virus, in combination with
toripalimab in patients with resectable stage IIIb to stage IVM1a
acral melanoma. J Clin Oncol. 39:9570. 2021. View Article : Google Scholar
|
|
112
|
Hyngstrom JR, Holmen S, Andtbacka RH,
William B, Tanaka M, Gravley W, David B, Hu-Lieskovan S and Van
Brocklin M: Neoadjuvant Canerpaturev (C-REV) Oncolytic
Immunotherapy in Combination with Nivolumab (Nivo) in Resectable
Advanced Melanoma. Pigment. Cell Melanoma Res. 35:1802022.
|
|
113
|
Cocorocchio E, Nezi L, Gandini S, Manzo T,
Mazzarella L, Lotti F, Pala L, Gnagnarella P, Conforti F,
Pennacchioli E, et al: 1072P Primary ipilimumab/nivolumab
immunotherapy followed by adjuvant nivolumab in patients with
locally advanced or oligometastatic melanoma: Update on outcome.
Ann Oncol. 32:S889–S890. 2021. View Article : Google Scholar
|
|
114
|
Najjar YG, McCurry D, Lin H, Lin Y, Zang
Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH,
et al: Neoadjuvant pembrolizumab and High-dose IFNα-2b in
resectable regionally advanced melanoma. Clin Cancer Res.
27:4195–4204. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Topalian SL, Bhatia S, Amin A, Kudchadkar
RR, Sharfman WH, Lebbé C, Delord JP, Dunn LA, Shinohara MM,
Kulikauskas R, et al: Neoadjuvant nivolumab for patients with
resectable merkel cell carcinoma in the CheckMate 358 trial. J Clin
Oncol. 38:2476–2487. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Fisher B, Gunduz N, Coyle J, Rudock C and
Saffer E: Presence of a growth-stimulating factor in serum
following primary tumor removal in mice. Cancer Res. 49:1996–2001.
1989.PubMed/NCBI
|
|
117
|
Fisher B, Saffer E, Rudock C, Coyle J and
Gunduz N: Effect of local or systemic treatment prior to primary
tumor removal on the production and response to a serum
growth-stimulating factor in mice. Cancer Res. 49:2002–2004.
1989.PubMed/NCBI
|
|
118
|
Bracci L, Schiavoni G, Sistigu A and
Belardelli F: Immune-based mechanisms of cytotoxic chemotherapy:
implications for the design of novel and rationale-based combined
treatments against cancer. Cell Death Differ. 21:15–25. 2014.
View Article : Google Scholar
|
|
119
|
Wei SC, Duffy CR and Allison JP:
Fundamental mechanisms of immune checkpoint blockade therapy.
Cancer Discov. 8:1069–1086. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Waser NA, Adam A, Schweikert B, Vo L,
McKenna M, Breckenridge M, Penrod JR and Goring S: Pathologic
response as early endpoint for survival following neoadjuvant
therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC):
Systematic literature review and meta-analysis. Ann Oncol. 31(Suppl
4): S744–S753. 2020. View Article : Google Scholar
|
|
121
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Menzies AM, Amaria RN, Rozeman EA, Huang
AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM,
Pennington TE, et al: Pathological response and survival with
neoadjuvant therapy in melanoma: A pooled analysis from the
International Neoadjuvant Melanoma Consortium (INMC). Nat Med.
27:301–309. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Chaft JE, Hellmann MD, Velez MJ, Travis WD
and Rusch VW: Initial experience with lung cancer resection after
treatment with T-cell checkpoint inhibitors. Ann Thorac Surg.
104:e217–e218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Bott MJ, Cools-Lartigue J, Tan KS, Dycoco
J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, et
al: Safety and feasibility of lung resection after immunotherapy
for metastatic or unresectable tumors. Ann Thorac Surg.
106:178–183. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
du Bois H, Heim TA and Lund AW:
Tumor-draining lymph nodes: At the crossroads of metastasis and
immunity. Sci Immunol. 6. pp. eabg35512021, View Article : Google Scholar
|
|
126
|
Fear VS, Forbes CA, Neeve SA, Fisher SA,
Chee J, Waithman J, Ma SK, Lake R, Nowak AK, Creaney J, et al:
Tumour draining lymph node-generated CD8 T cells play a role in
controlling lung metastases after a primary tumour is removed but
not when adjuvant immunotherapy is used. Cancer Immunol Immunother.
70:3249–3258. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Fransen MF, Arens R and Melief CJM: Local
targets for immune therapy to cancer: Tumor draining lymph nodes
and tumor microenvironment. Int J Cancer. 132:1971–1976. 2013.
View Article : Google Scholar
|
|
128
|
Mazieres J, Drilon A, Lusque A, Mhanna L,
Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et
al: Immune checkpoint inhibitors for patients with advanced lung
cancer and oncogenic driver alterations: Results from the
IMMUNOTARGET registry. Ann Oncol. 30:1321–1328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Lee CK, Man J, Lord S, Links M, Gebski V,
Mok T and Yang JC: Checkpoint inhibitors in metastatic EGFR-mutated
non-small cell lung cancer-a meta-analysis. J Thorac Oncol.
12:403–407. 2017. View Article : Google Scholar
|
|
130
|
To KKW, Fong W and Cho WCS: Immunotherapy
in treating EGFR-mutant lung cancer: Current challenges and new
strategies. Front Oncol. 11:6350072021. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Zhang C, Chen HF, Yan S, Wu L, Yan LX, Yan
XL, Yue DS, Xu CW, Zheng M, Li JS, et al: Induction
immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC:
A multi-center pooled analysis. NPJ Precis Oncol. 6:662022.
View Article : Google Scholar
|
|
132
|
Liu J, O'Donnell JS, Yan J, Madore J,
Allen S, Smyth MJ and Teng MWL: Timing of neoadjuvant immunotherapy
in relation to surgery is crucial for outcome. Oncoimmunology.
8:e15815302019. View Article : Google Scholar : PubMed/NCBI
|
